Table 1.

Demographic characteristics of neonates who received intravenous paracetamol

Characteristic	N [%]	Mean ± SD	Median [range]
Gestational age (weeks)	35 [100]	33.6 ± 6.57	37 [23–41]
Postnatal agea (days)	35 [100]	7.49 ± 5.73	6 [1–26]
Postmenstrual agea (weeks)	35 [100]	34.6 ± 6.28	37.6 [23.1–41.6]
Current body weighta (kg)	35 [100]	2.30 ± 1.22	2.80 [0.46–4.20]
Current body lengtha (cm)	34 [97]	43.4 ± 9.15	47.5 [25.0–56.0]
Current body weighta (kg) by gestational age subgroup
Extreme preterm (<28 weeks’ gestation)	10 [29]	0.81 ± 0.27	0.69 [0.55–1.30]
Preterm (<37 weeks’ gestation)	17 [49]	1.22 ± 0.76	0.96 [0.46–2.80]
Full term (37–42 weeks’ gestation)	18 [51]	3.32 ± 0.39	3.16 [2.70–4.20]
Serum creatinineb (mg/dL)	30 [86]	0.707 ± 0.242	0.65 [0.3–1.1]
Estimated GFRc (mL/min per 1.73 m2)	29 [83]	30.1 ± 16.6	24.1 [12.6–70.9]
Primary indication for intravenous paracetamol
Postoperative analgesia (cardiac surgery)	19 [54]
Procedural analgesia	16 [46]
Sex
Male	20 [57]
Female	15 [43]
Race
Caucasian	16 [46]
African American	14 [40]
American Indian/Alaska Native	1 [3]
Asian	1 [3]
Declined to respond	3 [9]
Ethnicity
Non-Hispanic	24 [69]
Hispanic	8 [23]
Declined to respond	3 [9]

GFR glomerular filtration rate, SD standard deviation

^aOn the day of the first paracetamol dose

^bSerum creatinine levels obtained at ≤3 days’ postnatal age were considered to reflect maternal renal function and were excluded from analysis

^cEstimated GFR was calculated using the updated Schwartz formula [27]